Woodcock Has Big, Quiet Supporter In Her Bid For US FDA Commissioner
Industry groups, along with many rare disease and patient advocacy groups, appear behind the acting commissioner getting the permanent position.
You may also be interested in...
US FDA Commissioner Race Shrinks And Widens: Biden Team Trying To Woo Reluctant Dems On Woodcock While Exploring New Options
White House is trying to overcome some Senate Democrats’ opposition to Janet Woodcock as FDA Commissioner, while also looking for other candidates for the job. Josh Sharfstein, long thought to be Woodcock’s main competition, is not a strong contender.
Of the two main contenders to lead FDA, Josh Sharfstein is seen as much more likely to open up review decisions to public scrutiny, while Janet Woodcock might be a vote for the status quo and more deferential to industry concerns.
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.